271 related articles for article (PubMed ID: 26448943)
1. The Diagnostic Ability of Follow-Up Imaging Biomarkers after Treatment of Glioblastoma in the Temozolomide Era: Implications from Proton MR Spectroscopy and Apparent Diffusion Coefficient Mapping.
Bulik M; Kazda T; Slampa P; Jancalek R
Biomed Res Int; 2015; 2015():641023. PubMed ID: 26448943
[TBL] [Abstract][Full Text] [Related]
2. Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.
Chu HH; Choi SH; Ryoo I; Kim SC; Yeom JA; Shin H; Jung SC; Lee AL; Yoon TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
Radiology; 2013 Dec; 269(3):831-40. PubMed ID: 23771912
[TBL] [Abstract][Full Text] [Related]
3. 3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy.
Muruganandham M; Clerkin PP; Smith BJ; Anderson CM; Morris A; Capizzano AA; Magnotta V; McGuire SM; Smith MC; Bayouth JE; Buatti JM
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):181-9. PubMed ID: 24986746
[TBL] [Abstract][Full Text] [Related]
4. Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
Kim JH; Choi SH; Ryoo I; Yun TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
PLoS One; 2014; 9(11):e113587. PubMed ID: 25419975
[TBL] [Abstract][Full Text] [Related]
5. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
[TBL] [Abstract][Full Text] [Related]
6. Advanced MRI increases the diagnostic accuracy of recurrent glioblastoma: Single institution thresholds and validation of MR spectroscopy and diffusion weighted MR imaging.
Kazda T; Bulik M; Pospisil P; Lakomy R; Smrcka M; Slampa P; Jancalek R
Neuroimage Clin; 2016; 11():316-321. PubMed ID: 27298760
[TBL] [Abstract][Full Text] [Related]
7. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
Wen Q; Jalilian L; Lupo JM; Molinaro AM; Chang SM; Clarke J; Prados M; Nelson SJ
J Neurooncol; 2015 Jan; 121(2):331-9. PubMed ID: 25351579
[TBL] [Abstract][Full Text] [Related]
8. MR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction.
Kim BR; Choi SH; Yun TJ; Lee ST; Park CK; Kim TM; Kim JH; Park SW; Sohn CH; Park SH; Kim IH
PLoS One; 2016; 11(11):e0166096. PubMed ID: 27835666
[TBL] [Abstract][Full Text] [Related]
9. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma.
Thomas AA; Arevalo-Perez J; Kaley T; Lyo J; Peck KK; Shi W; Zhang Z; Young RJ
J Neurooncol; 2015 Oct; 125(1):183-90. PubMed ID: 26275367
[TBL] [Abstract][Full Text] [Related]
10. Diffusion-weighted MR imaging for the differentiation of true progression from pseudoprogression following concomitant radiotherapy with temozolomide in patients with newly diagnosed high-grade gliomas.
Lee WJ; Choi SH; Park CK; Yi KS; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH
Acad Radiol; 2012 Nov; 19(11):1353-61. PubMed ID: 22884399
[TBL] [Abstract][Full Text] [Related]
11. Metabolic approach for tumor delineation in glioma surgery: 3D MR spectroscopy image-guided resection.
Zhang J; Zhuang DX; Yao CJ; Lin CP; Wang TL; Qin ZY; Wu JS
J Neurosurg; 2016 Jun; 124(6):1585-93. PubMed ID: 26636387
[TBL] [Abstract][Full Text] [Related]
12. Independent Poor Prognostic Factors for True Progression after Radiation Therapy and Concomitant Temozolomide in Patients with Glioblastoma: Subependymal Enhancement and Low ADC Value.
Yoo RE; Choi SH; Kim TM; Lee SH; Park CK; Park SH; Kim IH; Yun TJ; Kim JH; Sohn CH
AJNR Am J Neuroradiol; 2015 Oct; 36(10):1846-52. PubMed ID: 26294653
[TBL] [Abstract][Full Text] [Related]
13. Differentiation of intracranial tuberculomas and high grade gliomas using proton MR spectroscopy and diffusion MR imaging.
Peng J; Ouyang Y; Fang WD; Luo TY; Li YM; Lv FJ; Zhang ZW; Li XY
Eur J Radiol; 2012 Dec; 81(12):4057-63. PubMed ID: 22749802
[TBL] [Abstract][Full Text] [Related]
14. Measurements of diagnostic examination performance using quantitative apparent diffusion coefficient and proton MR spectroscopic imaging in the preoperative evaluation of tumor grade in cerebral gliomas.
Server A; Kulle B; Gadmar ØB; Josefsen R; Kumar T; Nakstad PH
Eur J Radiol; 2011 Nov; 80(2):462-70. PubMed ID: 20708868
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738
[TBL] [Abstract][Full Text] [Related]
16. Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging.
Zeng QS; Li CF; Liu H; Zhen JH; Feng DC
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):151-8. PubMed ID: 17289287
[TBL] [Abstract][Full Text] [Related]
17. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.
Pope WB; Kim HJ; Huo J; Alger J; Brown MS; Gjertson D; Sai V; Young JR; Tekchandani L; Cloughesy T; Mischel PS; Lai A; Nghiemphu P; Rahmanuddin S; Goldin J
Radiology; 2009 Jul; 252(1):182-9. PubMed ID: 19561256
[TBL] [Abstract][Full Text] [Related]
18. Non-invasive estimation of prostate cancer aggressiveness using diffusion-weighted MRI and 3D proton MR spectroscopy at 3.0 T.
Thörmer G; Otto J; Horn LC; Garnov N; Do M; Franz T; Stolzenburg JU; Moche M; Kahn T; Busse H
Acta Radiol; 2015 Jan; 56(1):121-8. PubMed ID: 24504488
[TBL] [Abstract][Full Text] [Related]
19. Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide.
Topkan E; Topuk S; Oymak E; Parlak C; Pehlivan B
Am J Clin Oncol; 2012 Jun; 35(3):284-9. PubMed ID: 21399487
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme.
Deviers A; Ken S; Filleron T; Rowland B; Laruelo A; Catalaa I; Lubrano V; Celsis P; Berry I; Mogicato G; Cohen-Jonathan Moyal E; Laprie A
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):385-93. PubMed ID: 25104068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]